Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: Results from ADVANCE in context of available evidence

Journal of Hypertension

Volumn 26, Issue SUPPL. 3, 2008, Pages

  Chalmers, John ^a   Joshi, Rohina ^a   Kengne, Andre Pascal ^a   Ninomiya, Toshiharu ^a   Bi, Yufang ^a   Bompoint, Severine ^a   Billot, Laurent ^a   Patel, Anushka ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

ADVANCE; Blood pressure; Cardiovascular disease; Diabetes mellitus; Efficacy; Indapamide; Perindopril; Safety

Indexed keywords

ANTIHYPERTENSIVE AGENT; INDAPAMIDE; PERINDOPRIL;

DRUG COMBINATION; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; INDAPAMIDE; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65549164301     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/01.hjh.0000334074.42823.77     Document Type: Review

References (37)

1. International Diabetes Federation. Diabetes atlas, 3rd ed. Brussels: International Diabetes Federation; 2006.
2. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28:2130-2135. (Pubitemid 41242456)
3. Danaei G, Lawes CMM, Vander Hoorn S, Murray CJL, ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006;368:1651-1659. (Pubitemid 46048553)
4. Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia Pacific region. Diabetes Care 2003;26:360-366.
5. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy: British trial shows clear effects of treatment, especially blood pressure reduction. BMJ 1998;317:693-694.
6. Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens Suppl 1993;11:309-317.
7. Baskar V, Kamalakannan D, Holland MR, Singh BM. Hypertension in diabetes: is there a place for age-adjusted centile cut-offs in those aged <50 years? Q J Med 2004;97:747-753. (Pubitemid 39462234)
8. Pechere-Bertschi A, Greminger P, Hess L, Philippe J, Ferrari P. Swiss Hypertension and Risk Factor Program (SHARP): cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. Blood Pressure 2005;14:337-344. (Pubitemid 43135731)
9. Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005;42(Suppl. 1):S17-S25.
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
11. Hansson L, Zanchetti A, Carruthers S, Dahlöf B, elmfeldt D, Julius S, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-1762. (Pubitemid 28269185)
12. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
13. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamideon macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-840.
14. ADVANCE Management Committee. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular Disease - PreterAx and DiamicroN MR Controlled Evaluation. Diabetologia 2001;44:1118-1120.
15. ADVANCE Management Committee. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 2001;19:S21-S28.
16. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al., on behalf of the UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419. (Pubitemid 30609443)
17. Asia Pacific Cohort Studies Collaboration. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 2007;25:1205-1213.
18. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
19. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 2005;165:1410-1419.
20. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007;25:951-958.
21. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
22. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist ibesartan in patients with nephropathy dueto type 2d iabetes. N Engl J Med 2001;345:851-860.
23. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878.
24. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-1792.
25. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; CD006257.
26. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, et al. Longterm effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000;57:590-600. (Pubitemid 30430651)
27. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351:28-31. (Pubitemid 28020163)
28. Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens Suppl 2000;18:327-337. (Pubitemid 30142850)
29. Mourad J, Waeber B, Zannad F, Laville M, Duru G, Andrejak M, on behalf of the investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach. J Hypertens 2004;22:2379-2386. (Pubitemid 39620288)
30. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38:922-926. (Pubitemid 34258694)
31. Dahlof B, Gosse P, Gueret P, Dubourg O, de Simone G, Schmieder R, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005;23:2063-2070. (Pubitemid 41830403)
32. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al. Effect of low-dose perindopril-indapamide on albuminura in diabetes. Preterax in Albuminuria Regression: PREMIER. Hypertension 2003;41:1063-1071. (Pubitemid 36548604)
33. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21:707-716.
34. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003;41:1341-1345. (Pubitemid 36706087)
35. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187. (Pubitemid 46924065)
36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-2572. (Pubitemid 37430158)
37. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care (partial update of NICE clinical guideline 18). Clinical guideline 34. June 2006. Available from: http://www.nice.org.uk. Accessed: 22 August 2006.